CA2677073C - Regulatory t cell epitopes, compositions and uses thereof - Google Patents

Regulatory t cell epitopes, compositions and uses thereof Download PDF

Info

Publication number: CA2677073C
Authority: CA; Canada
Prior art keywords: cells; tregitope; cell; regulatory; cell epitope
Prior art date: 2007-01-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

CA2677073A

Other languages

English (en)

French (fr)

Other versions

CA2677073A1 (en

Inventor

Anne De Groot

William Martin

Dan Rivera

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Epivax Inc

Original Assignee

Epivax Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-01-30

Filing date

2008-01-29

Publication date

2016-03-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39674696&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2677073(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-01-29 Application filed by Epivax Inc filed Critical Epivax Inc

2008-01-29 Priority to CA2915168A priority Critical patent/CA2915168C/en

2008-08-07 Publication of CA2677073A1 publication Critical patent/CA2677073A1/en

2016-03-15 Application granted granted Critical

2016-03-15 Publication of CA2677073C publication Critical patent/CA2677073C/en

Status Active legal-status Critical Current

2028-01-29 Anticipated expiration legal-status Critical

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Immunology (AREA)
Toxicology (AREA)
Hematology (AREA)
Diabetes (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Neurology (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Rheumatology (AREA)
Reproductive Health (AREA)
Biotechnology (AREA)
Mycology (AREA)
Orthopedic Medicine & Surgery (AREA)

CA2677073A 2007-01-30 2008-01-29 Regulatory t cell epitopes, compositions and uses thereof Active CA2677073C (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA2915168A CA2915168C (en)	2007-01-30	2008-01-29	Regulatory t cell epitopes, compositions and uses thereof

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US89834707P	2007-01-30	2007-01-30
US60/898,347		2007-01-30
PCT/US2008/001148 WO2008094538A2 (en)	2007-01-30	2008-01-29	Regulatory t cell epitopes, compositions and uses thereof

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2915168A Division CA2915168C (en)	2007-01-30	2008-01-29	Regulatory t cell epitopes, compositions and uses thereof

Publications (2)

Publication Number	Publication Date
CA2677073A1 CA2677073A1 (en)	2008-08-07
CA2677073C true CA2677073C (en)	2016-03-15

Family

ID=39674696

Family Applications (6)

Application Number	Title	Priority Date	Filing Date
CA2677073A Active CA2677073C (en)	2007-01-30	2008-01-29	Regulatory t cell epitopes, compositions and uses thereof
CA3161849A Pending CA3161849A1 (en)	2007-01-30	2008-01-29	Regulatory t cell epitopes, compositions and uses thereof
CA3034396A Active CA3034396C (en)	2007-01-30	2008-01-29	Regulatory t cell epitopes, compositions and uses thereof
CA2963138A Active CA2963138C (en)	2007-01-30	2008-01-29	Regulatory t cell epitopes, compositions and uses thereof
CA3001783A Active CA3001783C (en)	2007-01-30	2008-01-29	Regulatory t cell epitopes, compositions and uses thereof
CA2915168A Active CA2915168C (en)	2007-01-30	2008-01-29	Regulatory t cell epitopes, compositions and uses thereof

Family Applications After (5)

Application Number	Title	Priority Date	Filing Date
CA3161849A Pending CA3161849A1 (en)	2007-01-30	2008-01-29	Regulatory t cell epitopes, compositions and uses thereof
CA3034396A Active CA3034396C (en)	2007-01-30	2008-01-29	Regulatory t cell epitopes, compositions and uses thereof
CA2963138A Active CA2963138C (en)	2007-01-30	2008-01-29	Regulatory t cell epitopes, compositions and uses thereof
CA3001783A Active CA3001783C (en)	2007-01-30	2008-01-29	Regulatory t cell epitopes, compositions and uses thereof
CA2915168A Active CA2915168C (en)	2007-01-30	2008-01-29	Regulatory t cell epitopes, compositions and uses thereof

Country Status (11)

Country	Link
US (18)	US7884184B2 (2)
EP (13)	EP2450368A1 (2)
JP (10)	JP4866467B2 (2)
KR (3)	KR101722305B1 (2)
CN (4)	CN103755789B (2)
AT (1)	ATE525392T1 (2)
AU (1)	AU2008211227B2 (2)
CA (6)	CA2677073C (2)
IL (3)	IL200129A (2)
MX (3)	MX347197B (2)
WO (1)	WO2008094538A2 (2)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2450368A1 (en) *	2007-01-30	2012-05-09	Epivax, Inc.	Regulatory t cell epitopes, compositions and uses thereof
DE102007030904A1 (de) *	2007-07-03	2009-02-05	Pharis Biotec Gmbh	Humanes zirkulierendes antivirales Albumin-Fragment (ALB-408) und seine Verwendung
WO2012019168A2 (en)	2010-08-06	2012-02-09	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
EP2625189B1 (en)	2010-10-01	2018-06-27	ModernaTX, Inc.	Engineered nucleic acids and methods of use thereof
CN103561771B (zh)	2011-03-17	2019-01-04	伯明翰大学	重新定向的免疫治疗
AU2012236099A1 (en)	2011-03-31	2013-10-03	Moderna Therapeutics, Inc.	Delivery and formulation of engineered nucleic acids
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
DE19216461T1 (de)	2011-10-03	2021-10-07	Modernatx, Inc.	Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
RU2620070C2 (ru) *	2011-12-13	2017-05-22	Сантр Насьональ Де Ля Решерш Сьянтифик	Модифицированные пептиды и их применение для лечения аутоиммунных заболеваний
CA3018046A1 (en)	2011-12-16	2013-06-20	Moderna Therapeutics, Inc.	Modified nucleoside, nucleotide, and nucleic acid compositions
GB201203442D0 (en)	2012-02-28	2012-04-11	Univ Birmingham	Immunotherapeutic molecules and uses
WO2013151665A2 (en)	2012-04-02	2013-10-10	modeRNA Therapeutics	Modified polynucleotides for the production of proteins associated with human disease
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en)	2012-04-02	2016-02-09	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of proteins
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
PL2922554T3 (pl)	2012-11-26	2022-06-20	Modernatx, Inc.	Na zmodyfikowany na końcach
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
WO2015048744A2 (en)	2013-09-30	2015-04-02	Moderna Therapeutics, Inc.	Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en)	2013-10-03	2016-08-10	Moderna Therapeutics, Inc.	Polynucleotides encoding low density lipoprotein receptor
US20160310584A1 (en) *	2013-12-06	2016-10-27	The Broad Institute Inc.	Formulations for neoplasia vaccines
PL4023249T3 (pl)	2014-04-23	2025-03-10	Modernatx, Inc.	Szczepionki z kwasem nukleinowym
WO2016054114A1 (en)	2014-09-29	2016-04-07	The Regents Of The University Of California	Compositions for expanding regulatory t cells (treg), and treating autoimmune and inflammatory diseases and conditions
US10213482B2 (en)	2014-12-12	2019-02-26	Immupharma France Sa	Methods of treating chronic inflammatory diseases
US10441649B2 (en)	2015-02-02	2019-10-15	The University Of Birmingham	Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
CA3001725C (en)	2015-05-04	2021-06-15	Epivax, Inc.	Modified h7 hemaglutinin glycoprotein of the influenza a/shanghai/2/2013 h7 sequence
JP2018517405A (ja) *	2015-05-04	2018-07-05	エピバックスインコーポレーテッド	インフルエンザａ／上海／２／２０１３ｈ７配列の改変ｈ７赤血球凝集素糖タンパク質
FI3377103T4 (fi)	2015-11-19	2025-04-16	Revitope Limited	Funktionaalinen vasta-ainefragmenttikomplementointi kaksikomponenttiselle järjestelmälle epätoivottujen solujen uudelleenohjattua tappamista varten
PL238939B1 (pl) *	2016-11-02	2021-10-18	Instytut Immunologii I Terapii Doświadczalnej Polskiej Akademii Nauk Im Ludwika Hirszfelda We Wrocławiu	Peptyd immunosupresyjny i jego zastosowania
WO2019071116A1 (en) *	2017-10-05	2019-04-11	Epivax, Inc.	T REGULATORY LYMPHOCYTE EPITOPES
EP3622962A1 (en) *	2018-09-14	2020-03-18	advanceCOR GmbH	Short cyclic peptides for the treatment of graves' disease
EP3963335B1 (en) *	2019-05-03	2024-08-21	Epivax Therapeutics, Inc.	Neoantigens in cancer
AU2021243734A1 (en) *	2020-03-27	2022-09-01	Biotest Ag	Protein comprising at least one regulatory T cell activating epitope
EP4126901A4 (en) *	2020-03-27	2024-04-10	Epivax, Inc.	Regulatory t cell epitopes
CN111856020B (zh) *	2020-06-19	2022-09-27	南方医科大学南方医院	乙型肝炎病毒（hbv）特异性t细胞检测方法及其应用
US20230321237A1 (en) *	2020-08-13	2023-10-12	Epivax, Inc.	Regulatory t cell epitopes
AU2021350011A1 (en) *	2020-09-25	2023-05-11	Epivax, Inc.	Retro-inverso regulatory t cell epitopes
CA3225927A1 (en)	2021-07-16	2023-01-19	Vincent Dioszeghy	Immunotherapeutic method for increasing cashew tolerance in a subject
AU2024275787A1 (en)	2023-05-19	2025-11-27	Numab Therapeutics AG	Antibody variable domains and antibodies having decreased immunogenicity

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
FR2556219B1 (fr)	1983-12-07	1987-06-26	Merieux Inst	Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
GB8725529D0 (en)	1987-10-30	1987-12-02	Delta Biotechnology Ltd	Polypeptides
US5328470A (en)	1989-03-31	1994-07-12	The Regents Of The University Of Michigan	Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US6162432A (en)	1991-10-07	2000-12-19	Biogen, Inc.	Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5817308A (en) *	1994-02-14	1998-10-06	University Of Rochester	Tolerogenic fusion proteins of immunoglobulins and methods for inducing and maintaining tolerance
DE4425115A1 (de)	1994-07-15	1996-01-18	Boehringer Mannheim Gmbh	Verfahren zur Modifizierung der Stabilität von Antikörpern
US5705154A (en) *	1995-03-08	1998-01-06	Schering Corporation	Humanized monoclonal antibodies against human interleukin-4
ATE267610T1 (de)	1996-03-20	2004-06-15	Immunomedics Inc	Glykosylierte igg antikörper
WO1998034957A1 (en) *	1997-02-11	1998-08-13	Immunomedics, Inc.	STIMULATION OF AN IMMUNE RESPONSE WITH ANTIBODIES LABELED WITH THE α-GALACTOSYL EPITOPE
EP0979102A4 (en) *	1997-04-30	2005-11-23	Enzon Inc	DETAILED POLYPEPTIDE MODIFIED BY POLYALKYLENE OXIDE
US6953675B2 (en)	1997-11-06	2005-10-11	Immunomedics, Inc.	Landscaped antibodies and antibody fragments for clinical use
GB9809951D0 (en)	1998-05-08	1998-07-08	Univ Cambridge Tech	Binding molecules
DK1180159T3 (da)	1999-05-28	2008-11-17	Targeted Genetics Corp	Fremgangsmåder og sammensætninger til at sænke niveauet af Tumor-Nekrose-Faktor (TNF) i TNF-associerede lidelser
US6445840B1 (en)	1999-05-28	2002-09-03	Omm, Inc.	Micromachined optical switching devices
EP2213743A1 (en)	2000-04-12	2010-08-04	Human Genome Sciences, Inc.	Albumin fusion proteins
CA2415902A1 (en)	2000-07-10	2002-01-17	Xencor	Protein design automation for designing protein libraries with altered immunogenicity
BR0208041A (pt) *	2001-03-15	2004-02-25	Merck Patent Gmbh	Interferon beta modificado com imunogenicidade reduzida
WO2002079415A2 (en)	2001-03-30	2002-10-10	Lexigen Pharmaceuticals Corp.	Reducing the immunogenicity of fusion proteins
ATE469176T1 (de) *	2001-11-12	2010-06-15	Merck Patent Gmbh	Modifizierter anti-tnf antikörper
EP1453539B1 (en)	2001-12-05	2008-11-19	Circassia Limited	Immunotherapeutic methods and systems
AU2002364586A1 (en)	2001-12-21	2003-07-30	Delta Biotechnology Limited	Albumin fusion proteins
WO2003059934A2 (en)	2001-12-21	2003-07-24	Human Genome Sciences, Inc.	Albumin fusion proteins
WO2005003296A2 (en)	2003-01-22	2005-01-13	Human Genome Sciences, Inc.	Albumin fusion proteins
WO2003066824A2 (en)	2002-02-07	2003-08-14	Aventis Behring Gmbh	Albumin-fused kunitz domain peptides
US7317091B2 (en) *	2002-03-01	2008-01-08	Xencor, Inc.	Optimized Fc variants
EP1532262B1 (en)	2002-05-24	2013-07-10	Medtronic, Inc.	Peptide amidation process
US7285269B2 (en) *	2002-12-02	2007-10-23	Amgen Fremont, Inc.	Antibodies directed to tumor necrosis factor
CN1511958A (zh) *	2002-12-31	2004-07-14	王小宁	一种筛选人组织相容性抗原(hla)的t细胞表面抗原肽的体系,及其在制备mhc-抗原肽多聚体中的应用
WO2005035575A2 (en) *	2003-08-22	2005-04-21	Medimmune, Inc.	Humanization of antibodies
WO2005063815A2 (en)	2003-11-12	2005-07-14	Biogen Idec Ma Inc.	Fcϝ receptor-binding polypeptide variants and methods related thereto
EP1701979A2 (en) *	2003-12-03	2006-09-20	Xencor, Inc.	Optimized antibodies that target the epidermal growth factor receptor
DK2270045T3 (en)	2004-02-06	2015-04-07	Univ Massachusetts	ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINES AND APPLICATIONS THEREOF
HUE027902T2 (en)	2004-02-09	2016-11-28	Human Genome Sciences Inc Corp Service Company	Albumin fusion proteins
MXPA06010716A (es) *	2004-03-19	2007-02-21	Merck Patent Gmbh	Proteinas bouganin modificadas, citotoxinas y metodos y usos de las mismas.
EP1740615B1 (en) *	2004-03-31	2014-11-05	Genentech, Inc.	Humanized anti-tgf-beta antibodies
GEP20105110B (en)	2004-08-03	2010-11-10	Transtech Pharma Inc	Rage fusion proteins and their use
SG161242A1 (en)	2004-08-03	2010-05-27	Transtech Pharma Inc	Rage fusion proteins and methods of use
CU23504A1 (es)	2004-09-24	2010-04-13	Ct Ingenieria Genetica Biotech	Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas
US7488804B2 (en)	2005-02-02	2009-02-10	The Regents Of The University Of California	Modified fusion molecules for treatment of allergic disease
AU2006210724A1 (en) *	2005-02-03	2006-08-10	Antitope Limited	Human antibodies and proteins
CA2611814A1 (en)	2005-06-20	2007-01-04	Medarex, Inc.	Cd19 antibodies and their uses
WO2007021494A2 (en)	2005-08-12	2007-02-22	Human Genome Sciences, Inc.	Albumin fusion proteins
CN100349921C (zh) *	2005-11-17	2007-11-21	中国人民解放军第四军医大学	破伤风毒素t细胞表位多肽与人b淋巴细胞刺激因子融合蛋白及其制备
DK1969007T3 (da) *	2005-12-20	2013-11-25	Bristol Myers Squibb Co	Sammensætninger og fremgangsmåder til fremstilling af en sammensætning
CA2646508A1 (en) *	2006-03-17	2007-09-27	Biogen Idec Ma Inc.	Stabilized polypeptide compositions
GB0605735D0 (en)	2006-03-22	2006-05-03	Immunobiology Ltd	Composition and method for mediating an immune response
WO2007146038A2 (en)	2006-06-07	2007-12-21	Human Genome Sciences, Inc.	Albumin fusion proteins
AT503861B1 (de) †	2006-07-05	2008-06-15	F Star Biotech Forsch & Entw	Verfahren zur manipulation von t-zell-rezeptoren
AU2007284651B2 (en)	2006-08-09	2014-03-20	Institute For Systems Biology	Organ-specific proteins and methods of their use
EP2450368A1 (en) *	2007-01-30	2012-05-09	Epivax, Inc.	Regulatory t cell epitopes, compositions and uses thereof
AU2008261042A1 (en)	2007-06-08	2008-12-11	Dow Global Technologies Inc.	Expression of soluble antibody fragment by truncation of CH1 domain

2008
- 2008-01-29 EP EP12153170A patent/EP2450368A1/en not_active Withdrawn
- 2008-01-29 CN CN201310685046.7A patent/CN103755789B/zh not_active Expired - Fee Related
- 2008-01-29 AU AU2008211227A patent/AU2008211227B2/en not_active Ceased
- 2008-01-29 EP EP11177634.0A patent/EP2423222B2/en not_active Not-in-force
- 2008-01-29 WO PCT/US2008/001148 patent/WO2008094538A2/en not_active Ceased
- 2008-01-29 EP EP12153171A patent/EP2450369A1/en not_active Withdrawn
- 2008-01-29 EP EP15153373.4A patent/EP2896630B1/en not_active Not-in-force
- 2008-01-29 CN CN202011190692.2A patent/CN112279911A/zh active Pending
- 2008-01-29 EP EP12153166A patent/EP2450367A1/en not_active Withdrawn
- 2008-01-29 CA CA2677073A patent/CA2677073C/en active Active
- 2008-01-29 EP EP20110177630 patent/EP2423221B1/en not_active Not-in-force
- 2008-01-29 CA CA3161849A patent/CA3161849A1/en active Pending
- 2008-01-29 JP JP2009548278A patent/JP4866467B2/ja not_active Expired - Fee Related
- 2008-01-29 EP EP20110177625 patent/EP2423220B1/en not_active Not-in-force
- 2008-01-29 KR KR1020147024226A patent/KR101722305B1/ko not_active Expired - Fee Related
- 2008-01-29 CN CN201610958012.4A patent/CN107011431B/zh not_active Expired - Fee Related
- 2008-01-29 KR KR1020097017996A patent/KR20100014871A/ko not_active Ceased
- 2008-01-29 MX MX2015014429A patent/MX347197B/es unknown
- 2008-01-29 EP EP20120153174 patent/EP2450371B1/en not_active Not-in-force
- 2008-01-29 US US12/021,832 patent/US7884184B2/en active Active
- 2008-01-29 MX MX2009008230A patent/MX2009008230A/es active IP Right Grant
- 2008-01-29 CN CN200880011016.5A patent/CN101687912B/zh not_active Expired - Fee Related
- 2008-01-29 EP EP12153173A patent/EP2450370A1/en not_active Withdrawn
- 2008-01-29 EP EP20110177609 patent/EP2423219B1/en not_active Not-in-force
- 2008-01-29 CA CA3034396A patent/CA3034396C/en active Active
- 2008-01-29 CA CA2963138A patent/CA2963138C/en active Active
- 2008-01-29 EP EP12153164A patent/EP2450366A1/en not_active Withdrawn
- 2008-01-29 EP EP20120153177 patent/EP2450372B1/en not_active Not-in-force
- 2008-01-29 CA CA3001783A patent/CA3001783C/en active Active
- 2008-01-29 EP EP08713321.1A patent/EP2125883B2/en not_active Not-in-force
- 2008-01-29 CA CA2915168A patent/CA2915168C/en active Active
- 2008-01-29 AT AT08713321T patent/ATE525392T1/de not_active IP Right Cessation
- 2008-01-29 KR KR1020177008095A patent/KR20170037677A/ko not_active Ceased
2009
- 2009-07-28 IL IL200129A patent/IL200129A/en active IP Right Grant
- 2009-07-30 MX MX2018015933A patent/MX2018015933A/es unknown
2010
- 2010-12-29 US US12/981,098 patent/US20110182921A1/en not_active Abandoned
2011
- 2011-11-11 JP JP2011247226A patent/JP5643739B2/ja not_active Expired - Fee Related
2014
- 2014-07-30 JP JP2014154372A patent/JP6121369B2/ja not_active Expired - Fee Related
2015
- 2015-09-17 US US14/857,693 patent/US10213496B2/en active Active
2016
- 2016-05-04 IL IL245478A patent/IL245478B/en active IP Right Grant
2017
- 2017-03-29 JP JP2017064298A patent/JP6472476B2/ja not_active Expired - Fee Related
2018
- 2018-06-22 US US16/015,802 patent/US10925940B2/en not_active Expired - Fee Related
- 2018-06-22 US US16/015,828 patent/US11045530B2/en not_active Expired - Fee Related
- 2018-06-22 US US16/015,784 patent/US10751397B2/en active Active
- 2018-06-22 US US16/015,822 patent/US11045529B2/en not_active Expired - Fee Related
- 2018-06-22 US US16/015,814 patent/US11045528B2/en not_active Expired - Fee Related
- 2018-06-22 US US16/015,796 patent/US10925939B2/en not_active Expired - Fee Related
- 2018-06-22 US US16/015,837 patent/US11045531B2/en not_active Expired - Fee Related
- 2018-10-16 US US16/161,674 patent/US10925941B2/en not_active Expired - Fee Related
- 2018-10-16 US US16/161,671 patent/US11045532B2/en not_active Expired - Fee Related
2019
- 2019-01-22 JP JP2019008352A patent/JP2019089793A/ja active Pending
- 2019-03-04 US US16/291,658 patent/US10980867B2/en not_active Expired - Fee Related
- 2019-03-04 US US16/291,372 patent/US10925942B2/en not_active Expired - Fee Related
- 2019-06-10 IL IL267186A patent/IL267186B/en active IP Right Grant
- 2019-08-02 US US16/530,104 patent/US20190351036A1/en not_active Abandoned
2021
- 2021-01-28 JP JP2021011596A patent/JP2021073255A/ja not_active Withdrawn
- 2021-04-21 US US17/236,463 patent/US11844826B2/en active Active
- 2021-04-21 US US17/236,534 patent/US12016909B2/en active Active
- 2021-04-22 JP JP2021072455A patent/JP2021107444A/ja active Pending
- 2021-04-22 JP JP2021072446A patent/JP2021107443A/ja active Pending
2022
- 2022-01-14 US US17/576,321 patent/US20220211827A1/en not_active Abandoned
- 2022-09-29 JP JP2022155804A patent/JP2022177270A/ja active Pending
2024
- 2024-03-06 JP JP2024033497A patent/JP2024059975A/ja active Pending

Also Published As

Publication number	Publication date
CN112279911A (zh)	2021-01-29
EP2423222A1 (en)	2012-02-29
IL200129A0 (en)	2010-04-15
US20190351036A1 (en)	2019-11-21
US20190030143A1 (en)	2019-01-31
EP2450371B1 (en)	2015-04-29
JP2021073255A (ja)	2021-05-13
US10213496B2 (en)	2019-02-26
IL245478B (en)	2019-07-31
MX2009008230A (es)	2010-03-08
US7884184B2 (en)	2011-02-08
US20180289784A1 (en)	2018-10-11
EP2423221B1 (en)	2015-04-29
EP2896630B1 (en)	2020-12-23
US20180289786A1 (en)	2018-10-11
US20180289782A1 (en)	2018-10-11
EP2125883B1 (en)	2011-09-21
CA2963138A1 (en)	2008-08-07
US20210236609A1 (en)	2021-08-05
EP2423222B1 (en)	2015-04-29
US10925940B2 (en)	2021-02-23
JP2021107443A (ja)	2021-07-29
IL267186A (en)	2019-08-29
CA2915168C (en)	2017-05-23
US20090018067A1 (en)	2009-01-15
JP2022177270A (ja)	2022-11-30
EP2125883A2 (en)	2009-12-02
US20180289788A1 (en)	2018-10-11
US11045528B2 (en)	2021-06-29
IL200129A (en)	2016-10-31
CA3001783A1 (en)	2008-08-07
US10751397B2 (en)	2020-08-25
US11045532B2 (en)	2021-06-29
CN103755789B (zh)	2016-12-07
US20210252119A1 (en)	2021-08-19
US11045531B2 (en)	2021-06-29
US10980867B2 (en)	2021-04-20
EP2450370A1 (en)	2012-05-09
US20180289785A1 (en)	2018-10-11
US20160000892A1 (en)	2016-01-07
JP2014240404A (ja)	2014-12-25
IL267186B (en)	2020-01-30
EP2896630A1 (en)	2015-07-22
US11844826B2 (en)	2023-12-19
EP2125883B9 (en)	2014-04-23
EP2423222B9 (en)	2016-09-14
JP5643739B2 (ja)	2014-12-17
JP2010516290A (ja)	2010-05-20
AU2008211227A1 (en)	2008-08-07
IL245478A0 (en)	2016-06-30
CA2677073A1 (en)	2008-08-07
US11045529B2 (en)	2021-06-29
CN101687912B (zh)	2014-01-22
CA2963138C (en)	2019-05-14
US10925941B2 (en)	2021-02-23
EP2450366A1 (en)	2012-05-09
WO2008094538A3 (en)	2009-02-26
JP6121369B2 (ja)	2017-04-26
JP2019089793A (ja)	2019-06-13
EP2450372B1 (en)	2015-04-22
WO2008094538A2 (en)	2008-08-07
EP2423220B1 (en)	2015-04-29
AU2008211227B2 (en)	2014-04-17
MX347197B (es)	2017-04-18
CN101687912A (zh)	2010-03-31
EP2423219A1 (en)	2012-02-29
EP2450369A1 (en)	2012-05-09
ATE525392T1 (de)	2011-10-15
JP4866467B2 (ja)	2012-02-01
CA3034396A1 (en)	2008-08-07
EP2423219B1 (en)	2015-04-29
JP2024059975A (ja)	2024-05-01
MX2018015933A (es)	2021-11-16
US11045530B2 (en)	2021-06-29
US20190183994A1 (en)	2019-06-20
EP2450371A1 (en)	2012-05-09
US20220211827A1 (en)	2022-07-07
EP2423220A1 (en)	2012-02-29
EP2450368A1 (en)	2012-05-09
EP2450367A1 (en)	2012-05-09
US20180289787A1 (en)	2018-10-11
US20190183993A1 (en)	2019-06-20
JP2012087128A (ja)	2012-05-10
CN107011431A (zh)	2017-08-04
EP2423222B2 (en)	2020-07-29
US10925939B2 (en)	2021-02-23
JP2017165733A (ja)	2017-09-21
JP6472476B2 (ja)	2019-02-20
US20180289783A1 (en)	2018-10-11
CA2915168A1 (en)	2008-08-07
CA3161849A1 (en)	2008-08-07
CN103755789A (zh)	2014-04-30
US10925942B2 (en)	2021-02-23
US20190030144A1 (en)	2019-01-31
US20110182921A1 (en)	2011-07-28
EP2125883B2 (en)	2020-11-18
US12016909B2 (en)	2024-06-25
JP2021107444A (ja)	2021-07-29
KR20170037677A (ko)	2017-04-04
CN107011431B (zh)	2020-11-06
CA3034396C (en)	2022-08-02
EP2450372A1 (en)	2012-05-09
EP2423221A1 (en)	2012-02-29
KR20100014871A (ko)	2010-02-11
KR20140117662A (ko)	2014-10-07
KR101722305B1 (ko)	2017-03-31
HK1197250A1 (en)	2015-01-09
CA3001783C (en)	2020-09-08

Legal Events

Date	Code	Title	Description
2013-02-06	EEER	Examination request	Effective date: 20130128
2025-10-21	W00	Other event occurred	Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251021
2026-02-02	H13	Ip right lapsed	Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE Effective date: 20260202
2026-02-03	W00	Other event occurred	Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260203
2026-03-12	W00	Other event occurred	Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260312